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Tumour necrosis factor (TNF) is a pleiotropic cytokine with dual roles in cancer biology including prostate cancer (PCa). On the
one hand, there is evidence that it stimulates tumour angiogenesis, is involved in the initiation of PCa from an androgen-dependent
to a castrate resistant state, plays a role in epithelial to mesenchymal plasticity, and may contribute to the aberrant regulation of
eicosanoid pathways. On the other hand, TNF has also been reported to inhibit neovascularisation, induce apoptosis of PCa cells,
and stimulate antitumour immunity. Much of the confusion surrounding its seemingly paradoxical roles in cancer biology stems
from the dependence of its effects on the biological model within which TNF is investigated. This paper will address some of these
issues and also discuss the therapeutic implications.
1. Introduction
Cytokines are soluble, low molecular weight proteins that
mediate cell-cell communication. They are mainly produced
by immune cells and stromal cells (including fibroblasts and
endothelial cells) and act in concert to regulate biological
responses such as cell activation, proliferation, differentia-
tion, migration, and cytotoxicity. Cytokines have an integral
role in tumour induction and progression. They can facilitate
the generation and maintenance of robust antitumour
immune responses, but they can also contribute to chronic
inflammation and promote tumour formation, growth and
metastasis [1]. Whether the cytokine network within a given
tumour microenvironment is conducive or inhibitory for
tumour growth is highly dependent on the array of the
cytokines present, their relative concentrations, cytokine
receptor expression patterns, and the activation status of
cells that express these receptors. One cytokine that exhibits
dual roles in tumourigenesis is tumour necrosis factor-
alpha (TNF-α; also referred to as TNF). True to its name,
TNF is cytotoxic to tumour cells under certain conditions;
however, it also fuels tumour-promoting inflammation and
angiogenesis. This paper will discuss the function of TNF in
cancer biology, with special emphasis on PCa.
2. TNF Signalling
TNF is a multifunctional cytokine first isolated from the
serum of Bacillus Calmette-Guerin- (BCG-)infected mice
treated with endotoxin that could induce hemorrhagic
necrosis of tumours in mice [2]. It is synthesized as a
26 kD membrane-bound protein and cleaved into a 17 kD
soluble protein by TNF-converting enzyme (TACE) [3].
TNF is predominantly produced by macrophages, T cells
and natural killer (NK) cells, but nonimmune cells such
as fibroblasts, smooth muscle cells, and tumour cells have
also been reported to secrete low amounts of the cytokine
[4]. TNF signals via two distinct receptors: TNF receptor-1
(TNFR-1, p55 receptor), which is ubiquitously expressed,
and TNF receptor-2 (TNFR-2, p75 receptor), which is
mainly expressed on immune cells. TNFR-1 transduces both
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proapoptotic as well as prosurvival signals, although the
mechanisms that regulate the life or death outcome are
not well understood [4]. Upon binding to TNF, TNFR-1
trimerises, causing the silencer of death domain (SODD)
protein to be released from the DD of TNFR-1 [5]. This
permits the assembly of a complex composed of TNFR-
associated death domain (TRADD), TNFR-associated factor
2 (TRAF2), receptor-interacting protein (RIP), and FAS-
associated death domain (FADD) (together called complex
1) [5]. When TNFR-1 signals cell death, FADD binds to
procaspase-8, which triggers the activation of other caspases
and endonucleases that result in DNA fragmentation and
destruction of intracellular proteins, and eventually, apop-
tosis [4]. In another apoptosis-inducing pathway, TRAF2
activates the cascade signal regulating kinase (ASK-1), mito-
gen activated protein kinase-kinase 4 (MEK4), and Jun N-
terminal kinase (JNK), which then phosphorylates activator
protein-1 (AP-1), stimulating apoptosis [6]. When TNFR-1
signals survival, inhibitor of κB (IκB) kinase (IKK) is
recruited to complex 1 and is activated via RIP-dependent
mechanisms. The activated IKK phosphorylates IκB triggers
its ubiquitination then degradation in the proteasome;
hence allowing nuclear-factor- (NF-)κB to translocate from
the cytoplasm to the nucleus to promote transcription of
target antiapoptotic genes such as B-cell lymphoma extra-
large (Bcl-xL), A20, cellular inhibitor of apoptosis protein
(cIAP-)1 and 2 [5, 7]. Another antiapoptotic pathway is
triggered by the binding of TRAF2 with cIAP-1 [3]. TNFR-2
signaling mainly occurs on immune cells and endothelial
cells, and less is known about its mechanisms of signal
transduction. However, TNFR-2 lacks a death domain, but
can affect NF-κB and JNK signaling [3].
3. TNF as a Biomarker of PCa
An ideal cancer biomarker is one that allows for early
detection of disease and/or assessment of response to therapy
and prognosis, is minimally invasive to the patient when
sampled, and cost effective to be assayed [8]. Since cytokines
are often involved in the evolution of cancers, measuring
their levels in bodily fluids may provide a reflection of the
patient’s pathological state. Serum TNF levels have been
shown to be reflective of tumour load in PCa patients being
low in healthy men (mean 1.1 ± 0.5 pg/mL), higher in
patients with bulky locally-advanced PCa (3.9± 3.4 pg/mL),
and highest in those with metastatic disease (lymph node
and bone involvement) (6.3±3.6 pg/mL) [9]. When patients
develop symptomatic progressive disease, serum TNF levels
also significantly elevate from initial presentation. A uni-
variate analysis of serum TNF levels in relation to survival
showed that patients with locally-advanced PCa and high
TNF (> 1.9 pg/mL; cut-off defined as the 95th percentile of
values in control group) had significantly shorter survival as
compared to their counterparts with low TNF (P = 0.04)
[9]. As PCa patients often experience cachexia (weight loss,
anorexia, anaemia, and metabolic abnormalities), a study
evaluated the relationship between this disease complication
and serum TNF levels. Patients with elevated serum TNF
(defined as > 2 units/mL) have lower levels of serum albumin
and hemoglobin, lower body mass index, and shorter
survival time [10]. Similarly, high serum TNF correlates
with increases in plasma levels of thrombin-antithrombin-
III complex, plasmin-α2-antiplasmin inhibitor complex, and
soluble fibrin monomer complex, hence, linking TNF with
coagulopathy in PCa [11]. While it cannot be ascertained
from these studies whether the elevated TNF contributes to
disease progression, or is a reflection of advanced disease,
it is clear that TNF is a potential PCa biomarker, and more
research into its clinical diagnostic and prognostic utility is
warranted.
In prostatic tissues, TNF expression levels correlate with
disease progression, with immunostaining for TNF reported
to be absent on normal prostatic (NP) epithelial cells, weak
on benign prostatic hyperplasic (BPH) tissues but strong
on prostatic carcinomas [12]. Similarly, both BHP and PCa
express significantly higher levels of TNFR-1 and TNFR-2
as compared to the NP tissue [13]. This observation is
consistent with findings from a recent study which analysed
genome wide methylation in PCa [14]. The TNFRSF1B
gene, which encodes TNFR-2, was hypo-methylated by 3-
fold in PCa samples, whilst the two genes, BCL-2 and
BAK1, which are involved in TNF-dependent apoptosis
pathways, were found to be hyper-methylated, resulting in
their downregulation [14]. Evidence for alterations in TNF-
mediated apoptosis pathways in PCa was also provided by
another study where immunostaining for TRAF-2, ASK-1,
MEK-4 and JNK (involved in proapoptotic pathway) was
intense on biopsies from normal prostates, weaker in BHP
but absent in PCas, which may in part account for resistance
to TNF-mediated death by in PCa [6]. On the other hand,
immunostaining for NF-κB inducing kinase (NIK), IKK,
IκBα, p-Iκβ, p50, and p65 (involved in TNF-mediated
prosurvival pathway) was progressively elevated from NP to
BHP, and to PCa [15].
4. Role of TNF in Initiation and Progression
of PCa to a Hormone-Refractory State
PCa is regulated by androgen dependent gene pathways.
Despite effective surgery or radiation therapy, over 25% of
patients will suffer a relapse and face hormone deprivation
therapy (ADT) which improves the time to clinical progres-
sion and symptom management [16]. ADT effectiveness is
due to the requirement for androgens by the prostate gland
and PCa for growth and survival [17]. Androgen removal
thus initially induces tumour regression and a period of
cancer control. Therapeutic approaches to ADT have evolved
from surgical castration to safer, direct approaches that
interfere with the hypothalamic gonadal axis for testosterone
synthesis [18]. The past 3 decades have seen additional
and sequential use of androgen receptor (AR) antagonists
that bind directly to the AR to inhibit its action [19].
The AR is a ligand regulated receptor; upon binding the
physiological androgen, dihydrotestosterone (DHT), the AR
serves to activate and repress a large set of responsive genes
that control growth, stress, proliferation, differentiation, and
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cell survival. While these therapies are highly effective and
lead to remissions typically lasting 2-3 years, all patients
will eventually develop castrate resistant prostate cancer
(CRPC), which has no cure [20]. Treatment relapse is
partly due to the ability of CRPC to undertake de novo
steroidogenesis and synthesis of androgens and other steroids
that reactivate the AR [21]. Emerging evidence indicates
that TNF has key roles in both castration-induced regression
of the normal prostate, as well as in PCa progression to
a castrate resistant state. A recent study showed that after
surgical castration of mice, the prostates from TNF−/− mice
regressed significantly more slowly than those from wild-
type mice, and that regression could be restored following
administration of soluble TNF [22]. The slower rate of
castration-induced prostate regression was also observed in
TNFRI−/− mice, suggesting that TNF death signalling is
required for normal prostate regression [22]. In addition, the
authors demonstrated that membrane-bound TNF increased
by 2-fold in the ventral prostate of rats following castration,
and that this was paralleled with a 50–500-fold increase in
mRNA level of TNF within the stromal compartment of the
ventral prostate, suggesting that the stroma could be a rich
source of regression-mediating TNF. However, studies using
the androgen sensitive cell line, LNCaP, also provide evidence
that TNF may be involved in the progression of PCa to a
castrate resistant state. TNF was shown to dose-dependently
decrease the expression of the androgen receptor (AR) and
inhibit dihydrotestosterone (DHT)-induced proliferation of
LNCaP cells, suggesting that TNF may play a role in the
initiation of an androgen-independent state in these cells
[12]. In LN-TR2 cells, a subline of LNCaP cells derived
from long term culture in low levels of TNF, maximal DHT-
induced cell proliferation was achieved with 10-fold less
DHT as compared to that required for the parental cells
[23]. In addition, LN-TR2 cells showed higher expression of
nuclear AR as well as the AR coactivators, androgen receptor
associated protein-55 (ARA55), and transcriptional inter-
mediary factor-2 (TIF2), which correlated with enhanced
transcriptional activity of AR and prostate specific antigen
(PSA) [23, 24]. These results indicate that chronic exposure
to low amounts of TNF induces hypersensitivity to androgen
in LNCaPs; and this mechanism could play a role in
hormone-resistance, at least in some patients with PCa.
5. TNF Acts as a Double-Edged Sword in
Tumour Progression
TNF exhibits both tumour-promoting and tumour-
inhibitory properties, depending on the experimental
context within which the conclusions are made (Table 1).
There is evidence that chronic synthesis of low amounts
of TNF within a tumour microenvironment promotes
tumour growth and favours angiogenesis, whereas higher
doses can induce necrosis of tumour cells, stimulate
antitumour immunity, and trigger vascular collapse
[25, 26]. It is now accepted that chronic inflammation
is a major risk factor for carcinogenesis, and emerging
evidence shows that TNF has key roles in this process [26].
In a de novo carcinogenesis model in which the carcinogens
7,12-dimethylbenz[α]anthracene (DMBA) and 12-O-
tetradecanoyl-phorbol-13-acetate (TPA) were applied to
the skin of mice, TNF−/− mice were significantly more
resistant to tumour induction than wild-type animals [27].
TNF−/− mice had a lower incidence of total tumours,
and where these did develop, there was a delay in onset
as compared to those in wild-type mice. Histologically,
tumours from wild-type mice contained a heavy infiltrate
of inflammatory neutrophils and eosinophils, whereas
only a mild infiltrate was seen in tumours from TNF−/−
mice [27]. In addition, the skin of TNF−/− mice contained
lower levels of myeloperoxidase (MPO), a constituent of
neutrophil granules which contribute to carcinogenesis via
the generation of DNA-damaging reactive oxygen species
and hypochlorous acid [28]. These results collectively show
that TNF has a profound effect on the make-up of the stroma
during tumour development.
TNF also has a role in neovascularisation, which may
have implications for tumour angiogenesis. At low concen-
trations (0.5–50 ng/mL), TNF induces in vitro chemotaxis
of bovine adrenal capillary endothelial cells and induces the
formation of branching capillary-tube-like structures, but
these effects are inhibited at high TNF doses (500 ng/mL)
[29]. Lower levels of TNF (0.05–0.5U/mL) have been
shown to stimulate the proliferation of basic fibroblast
growth factor-stimulated adrenal cortex-derived capillary
endothelial cells, but increased doses (5–50U/mL) inhibit
proliferation in a dose-dependent manner [30]. In vivo,
TNF also induces capillary blood vessel formation in the rat
cornea and the developing chick chorioallantoic membrane
at very low concentrations (3.5 and 1 ng, resp.) [29].
Moreover, subcutaneous implantation in mice with a poly-
vinyl-alcohol foam disk containing low doses of TNF (0.01–
1 ng) induced angiogenesis, whereas at high doses (up to
5 ng) angiogenesis was inhibited [34]. Therefore, TNF can
have bimodal, dose-dependent opposing effects within the
context of neovascularisation.
The ability of this cytokine to suppress the proliferation
of endothelial cells under some conditions renders it as
a potential antitumour angiogenesis agent, if strategically
delivered to the tumour site. Indeed, a fusion protein
composed of mouse TNF and a high affinity antibody frag-
ment to the extradomain B (ED-B) domain of fibronectin,
a marker of angiogenesis, induced significant antitumour
activity against subcutaneously grown F9 embryonal terato-
carcinoma, an effect attributed by the authors to targeting of
the tumour vasculature [40]). The activity of this agent was
enhanced when used in combination with the chemothera-
peutic drug, melphalan; it was suggested that this synergism
was in part due to the effects of TNF on the vasculature,
including reduction of interstitial pressure and an increase
of vascular permeability that ultimately led to enhanced
tumour accumulation of melphalan [40, 41]. The use of
targeting approaches to facilitate incorporation of TNF into
tumour vasculature has also been investigated in preclinical
models of PCa, whereby coupling TNF with the CNGRC
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Table 1: Summary of potential protumour and antitumour roles of TNF in PCaPCa.
Protumour Reference
Involvement in the initiation of castrate resistant PCa by inducing hypersensitivity to androgen (LNCaP cells) [12]
Induces neutrophil production of myeloperoxidase, which generates carcinogenic reactive oxygen species (ROS) and
hypochlorous acid
[27]
Induces in vitro chemotaxis and proliferation of endothelial cells at low doses [29, 30]
Upregulates E-, P-, and L-selectin ligands on LNCaP cells, which may facilitate extravasation to bloodstream [31]
Increases expression of MMP-9, fibronectin and decreases E-Cadherin by PC-3 cells [32]
Involvement in epithelial-mesenchymal plasticity via Snail [32]
May stimulate tumour proliferation and reduce apoptosis via PGE2 [33]
Antitumour Reference
Induces regression of normal prostate [22]
Inhibits in vitro and in vivo angiogenesis at high doses [30, 34]
Induces apoptosis of LNCaP cells [35, 36]
Stimulates antitumour immunity by enhancing the generation and proliferation of cytotoxic T cells (CTL)
Also prevents TGF-β-mediated inhibition of CTL generation
[7, 37, 38]
Induces production of other cytokines (e.g., IL-1, IL-6, IL-8, and IFN-γ) and cytotoxic factors (e.g., NO and ROS) by
macrophages and NK cells
[7]
Protects dendritic cells from tumour-induced apoptosis [39]
peptide, a ligand for CD13 which is expressed on tumour
vessels, enhanced the therapeutic index of doxorubicin
against TRAMP C1 mouse prostate tumours in vivo [42].
While TNF has been shown to promote tumour pro-
gression through its role in chronic inflammation, it is also
important to note that TNF may also directly endow tumour
cells with greater metastatic potential. As tumour cells begin
to metastasise, they invade and migrate towards endothelial
cells in order to enter the bloodstream. This process involves
dynamic interactions between selectins expressed on stromal
cells for example, endothelial cells, and selectin ligands on
cancer cells [43]. TNF has been shown to enhance the in vitro
migration and invasion of LNCaP cells through increasing
the expression of several glycosyl- and sulfo-transferase genes
that are involved in the synthesis of mucin-type selectin
ligands [31]. As a result, TNF enhanced the binding of
LNCaP cells to E, P, and L selectins, which may facilitate
the entry of tumour cells into the bloodstream. TNF has
also been shown to induce in vitro invasion of PC-3 cells;
this increased invasion was accompanied by an increase
in their expression of matrix metalloproteinase (MMP-)9
and fibronectin, and a decrease in E-Cadherin [32]. These
effects were shown to be mediated through the zinc-finger
transcriptional repressor, Snail, as Snail siRNA prevented
TNF-induced cell invasion [32]. Therefore, it is conceivable
that low amounts of TNF within a chronically inflamed
tumour microenvironment may help drive tumour cells to
undergo epithelial to mesenchymal plasticity and spread to
form secondary tumours. As PCa frequently metastasises
to bone forming lesions with a predominantly osteoblastic
phenotype [44], it is worthwhile to highlight a potential
role for TNF in this process. RAW 264.7 pre-osteoclast cells
cultured with conditioned media from LNCaP-C4-2B cells
prestimulated with recombinant TNF had a 5-fold decrease
in gene expression of NF-κB ligand (RANKL), a suppressor
of osteoclastogenesis, as compared to LNCaP-C4-2B cells
without TNF [45]. Moreover, conditioned media from TNF-
stimulated LNCaP-C4-B2 cells [46] induced in vitro miner-
alisation of MC3T3-E1 osteoblast-like cells, suggesting that
TNF within the tumour microenvironment could play a role
in bone remodelling and promote osteoblastic activity [45].
Despite abundant evidence to suggest that TNF has a
role which favours tumour progression, this cytokine was
originally identified as a factor that strongly induced tumour
necrosis, hence its name. In PCa, TNF has been shown
to dose-dependently induce apoptosis of LNCaP cells [35,
36] and also to sensitise these cells to gamma irradiation-
induced apoptosis in vitro and in vivo [47, 48]. However,
the finding that LNCaP derived cell lines, C4, C4-2, and
C4-2B, all of which are resistant to androgen deprivation
are also resistant to TNF [49] suggests that the sensitivity
of PCa cells to TNF may play a role in their androgen
responsiveness. Supporting this hypothesis is the observation
that TRADD expression is significantly lower in these cell
lines, and that androgen deprivation actively suppresses
TRADD expression in LNCaP cells [49]. While TNF has
limited efficacy in directly inducing apoptosis of androgen-
independent PCa cell lines such as PC-3 and DU145 [50],
TNF still may have therapeutic potential, based on its ability
to stimulate antitumour immunity. TNF is a pleiotropic
cytokine, which when strategically delivered to tumours
locally, may result in therapy-induced inflammation that
could be protective against tumours [51]. This is because the
net effect of tumour-associated inflammation is dependent
on a fine balance between tumour-promoting and tumour-
inhibiting actions [51]. TNF may contribute to protective
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therapy-induced inflammation by inducing the production
of other cytokines (e.g., IL-1, IL-6, IL-8, interferon (IFN-)γ)
and cytotoxic factors (e.g., nitric oxide and reactive oxygen
species) by macrophages and NK cells and enhancing the
proliferation of T cells alone or synergistically with IL-6
[7, 37]. TNF also promotes the generation of cytotoxic T
cells (CTL), and protects them from transforming growth
factor (TGF)-β-mediated inhibition [38]. Mice deficient in
TNF have been shown to be unable to reject syngeneic
MC57X fibrosarcomas, but can do so when recombinant
TNF is administered [52]. In addition, CTL and NK cells
derived from these mice displayed impaired cytotoxicity
against tumour cells. In another study, TNF−/− but not wild-
type mice failed to recruit NK cells to the peritoneum, the
site where a variety of tumour cells including RM1 murine
PCa, have been injected [53]. TNF also protects against RM1
PCa-induced apoptosis of dendritic cells, which are antigen
presenting cells pivotal in the development of protective
antitumour immunity [39]. These results collectively show
that TNF can have direct tumour inhibitory effects as well
as roles in immune potentiation, which should be exploited
in cancer immunotherapies. For these reasons, TNF is often
included in protocols of dendritic cell-based cancer vaccines
[54].
6. Potential Role of TNF in
Eicosanoid Pathways in PCa
Eicosanoids, the oxidative metabolites of the essential fatty
acid arachidonic acid, are a focus of increasing interest
due to a growing body of evidence across broad disciplines
that these products may contribute to the development and
progression of PCa [55, 56]. The metabolic pathways that
control their production have thus become targets for the
development of novel agents to treat this disease because
these pathways appear to be aberrantly induced in PCa
tissues. Progress is limited largely by the preliminary nature
of the field and our poor understanding of the quantitative
biochemistry of this complex pathway in PCa. There are over
100 eicosanoid products known in humans, many of which
are biologically active and their production and metabolism
is controlled by at least 40 enzymes with some products being
formed by nonenzymatic-oxidative reactions [57, 58].
Given this complexity and lack of knowledge, a key
strategy has been to identify and target factors that regulate
the pathway, rather than individual biosynthetic enzymes,
in the hope that blockade of these regulators will have a
broader benefit. Arachidonic acid flux to the eicosanoid
pathways in PCa tissues, as in other tissues, appears to be
mediated primarily by one of the 20 known mammalian
phospholipase A2 enzymes, cPLA2-α (Group IVA PLA2).
cPLA2-α is expressed in PCa and pharmacological inhibition
of this enzyme results in reduction of tumour size in a PCa
xenograft model [59]. This intracellular enzyme is activated
by external receptor mediated signals that mobilise calcium
or phosphorylate mitogen and/or stress activated kinase
pathways, in particular the ERK, p38, and JNK. In chronic
inflammatory conditions, the proinflammatory cytokines,
including TNF, are important activators of this enzyme and
blockade of these cytokines effectively limits the flux of
arachidonic acid to the pathway [60].
A second important regulatory feature of the eicosanoid
pathway is that, in addition to a cell-type and tissue-specific
complement of constitutively present biosynthetic pathway
enzymes that define the range of eicosanoid products
made under normal physiological conditions, key pathway
enzymes have duplicated genes whose expression is respon-
sive to stress signals such as cytokine activation. Induction of
these genes results in a rapid increase in the capacity of the
eicosanoid pathways to metabolise arachidonic acid. Several
of these genes, notably a secreted phospholipase A2 (Group
IIA PLA2, hGIIA, sPLA2-IIA) [55] and cyclooxygenase-
2 (COX-2) [61], are aberrantly overexpressed at defined
stages of PCa progression. In cultured cells and in tissues,
inflammatory cytokines, including TNF, are potent inducers
of this gene expression, again through activation of mitogen
activated protein kinase and NF-κB signalling pathways.
There is growing evidence that inappropriate expression
of inflammatory cytokines including TNF may contribute
to the aberrant regulation of eicosanoid pathways in PCa.
TNF transiently induces steady-state COX-2 protein and
mRNA levels over constitutively high basal levels (prostate
tissue has unusually high levels of COX-2 relative to other
human tissues) in normal prostate epithelial cells [33]. This
increase correlates with increased prostaglandin E2 (PGE2)
production and reduced apoptosis. In PCa cells, COX-2 is
barely detectable without stimulation, but is inducible by
TNF. Importantly, the time course of induction [33] and the
quantitative production of PGE2 [62] on TNF stimulation
is variable between cell lines indicating that TNF signalling
is significantly and variably altered, but not ablated in these
cells. TNF stimulation of tumour cells may thus directly
induce aberrant PGE2 production, affecting downstream
regulation of proliferation and apoptosis by PGE2. Further,
increased TNF production by surrounding normal cells
due to inappropriate TNF expression in the prostate may
contribute to increased paracrine PGE2 production, thereby
indirectly suppressing apoptosis in cancer cells through
PGE2 signalling [33].
Induction of cytokine gene expression, including TNF,
can be demonstrated in cultured PC-3 cells following addi-
tion of arachidonic acid [63]. This induction is suppressed
by pharmacological blockade of PI3 kinase or COX enzymes
and correlates with increased phosphorylation of the AKT,
without phosphorylation of the MAP kinase pathways ERK,
p38, or JNK. Thus TNF stimulation of the eicosanoid
pathway may serve to indirectly activate other growth stim-
ulatory signalling pathways and to further amplify cytokine
production, even in the absence of immune cell infiltration.
In combination, these data provide evidence that TNF
may contribute to PCa growth by directly and indirectly
modulating pathways that stimulate proliferation and reduce
apoptosis of cancer cells. Studies aimed at blockade of TNF
in vivo appear warranted in an effort to determine the
relative importance of this cytokine over other factors such as
stimulators of the HER/HER2 pathway [64] that may activate
eicosanoid-related growth stimulatory pathways in PCa.
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7. A Perspective on TNF Therapy
Much of the confusion relating to the function of TNF in
cancer can be attributed to the dependence of its effects on
the biological context within which the cytokine has been
investigated. Variables such as cytokine dose, target cell type,
hormone sensitivity of the cell type, and the complexity of
the system (in vitro versus in vivo) can greatly influence
the type of activity seen to be exerted by TNF. By virtue
of its dual role in tumour biology, it may appear at face
value that TNF would have limited therapeutic utility against
cancers because its protumour properties would nullify its
antitumour effects. However, here we propose two TNF-
centred therapeutic approaches which are rational for the
treatment of PCa. The first approach is to neutralise TNF
in patients with androgen-sensitive non-metastatic disease.
Since TNF is central in chronic inflammation (important
in tumour initiation and progression), drives epithelial to
mesenchymal plasticity (facilitating metastasis), is involved
in the progression of prostate tumours from an androgen-
sensitive to CRPC, and may contribute to the aberrant
regulation of eicosanoid pathways (stimulate proliferation
and reduce apoptosis), then blockade of TNF could keep PCa
progression in check. In addition, since elevated serum levels
of TNF correlate with increased likelihood of cancer-related
cachexia and coagulopathy, neutralisation of TNF may also
have palliative effects. A recent pilot study provided anec-
dotal evidence that neutralisation of TNF may benefit some
patients with advanced PCa [65]. Transient pain relief from
bonemetastases was noted in 2 of 6 patients who received the
TNF-blocking antibody, infliximab.While disease progressed
in all patients, no treatment-related adverse events were
noted. It is important to note that TNF also contributes
to Rheumatoid Arthritis by fuelling chronic inflammation,
inducing angiogenic factors, modulating the expression of
adhesion molecules, and enhancing production of MMPs,
and that TNF antagonists have had tremendous clinical
success for the treatment of this disease [66]. All of these
processes are also implicated in tumour-associated chronic
inflammation; therefore, it is conceivable that blockade of
TNF could be efficacious against early-stage PCa.
The second therapeutic strategy we propose is targeted-
delivery of TNF to the tumour site. The rationale is based
on the direct effects of TNF in destroying the tumour
vasculature at high doses, and on its effects in stimulating
antitumour immunity. Locally delivered high dose TNF in
combination with melphalan is already a well-established
treatment protocol for soft tissue sarcoma (STS), and
melanoma in-transit metastases confined to the limb [4].
In this setting, the ability of TNF to modulate the tumour
vasculature has been exploited, allowing for greater accumu-
lation of the chemotherapeutic drug within the tumour. As
TNF shows a broad spectrum of effects on immune cells,
it also has potential to be used as an immunotherapy for
PCa. The rationale is to administer sufficient doses of TNF to
the tumour to induce acute inflammation, which frequently
precedes the development of adaptive antitumour immunity
[51]. In a clinical trial involving 10 patients with locally
advanced hormone-resistant PCa, intratumoural injection
with recombinant TNF at 4-week intervals combined with
intermittent subcutaneous injection of IFN-α2b, induced
a significant reduction in prostate volume in 9 patients
[67]. Tumour necrosis was found in biopsy samples from
all patients, some of which contained a heavy infiltration
of macrophages and NK cells, indicating local cytotoxic
effects by the cytokine [67]. The rationale for delivering
TNF to the tumour site as a therapeutic approach is further
supported by a clinical trial showing no clinical activity by
TNF when administered systemically daily for 5 consecutive
days in patients with androgen-independent PCa [68].
In addition, severe dose-limiting toxicities were observed.
Methods of cytokine delivery that warrant investigation
include intratumoural injection of TNF, conjugation of
TNF-coated/carrying nanoparticles to antibodies specific for
prostate antigens, and gene therapy approaches whereby
expression of this cytokine is driven by prostate-specific
promoters. Further support for this therapeutic approach
comes from the strong antitumour effects achieved through
tumour expression/local delivery of other proinflammatory
cytokines including IL-2 [69], granulocyte macrophage-
colony stimulating factor (GM-CSF) [70], and IL-18 alone
[71] or a combination with IL-12 [72] which have been
reported in preclinical in vivo models of PCa. Based on
the integral role of TNF in promoting and inhibiting PCa
growth, TNF is a potential biomarker for the disease and
research into its therapeutic utility needs to continue.
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